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Abstract 
   5-Fluorouracil (5-FU) is a drug that belong to the antimetabolite class of antineoplastic agents, with a broad spectrum of 
activity against solid tumors, the use of oral 5-FU was abandoned decades ago because of its irregular absorption and 
rapid degradation. A potential strategy to improve the selective properties of 5-FU is the chemical transformation into 
reversible derivatives (prodrugs) which are converted to the parent drug by virtue of enzymatic or chemical means. In the 
present study, three derivatives of 5-fluorouracil have been designed to be synthesized as an azo derivatives of 5-
fluorouracil in order to selectively deliver 5-fluorouracil into the cancer cells of the colon. The synthesis of the target 
compounds were accomplished following multistep reaction procedures. The chemical reactions were followed up and 
purity of the products was checked by TLC. The structure of the final compounds and their intermediates were 
characterized and identified by their melting points, infrared spectroscopy and elemental microanalysis. Compounds 2 and 
3 were subjected to a stability study in phosphate buffer (pH 1.5 and 7.8) for different time intervals (0 – 240 min) at 37°C. 
Keywords: 5-fluorouracil; colorectal cancer; prodrug approach; Colon- specific drug delivery. 
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1. Introduction 
The aim of most cancer chemotherapeutic drugs currently in clinical use is to kill malignant tumor cells by inhibiting some 
of the mechanisms implied in cellular division. However, the knowledge of tumor biology has exploded during the past 
decades and this may pave the way for more active, targeted anticancer drugs 
(1)
. It is obvious that cancer chemotherapy 
is a very difficult task 
(2)
. One of its main associated problems is the nonspecific toxicity of most anticancer drugs due to 
their biodistribution throughout the body, which requires the administration of a large total dose to achieve high local 
concentrations in a tumor. Drug targeting was aimed at preferred drug accumulation in the target cells independently on 
the method and route of drug administration 
(3)
. One approach that allows improving the selectivity of cytotoxic compounds 
is the use of prodrugs that are selectively activated in tumor tissues, taking advantage of some unique aspects of tumor 
physiology, such as selective enzyme expression, hypoxia, and low extracellular pH 
(4)
. Colorectal cancer (CRC) is a type 
of cancer that starts in the colon or rectum portion of large intestine in the gastrointestinal (GI) tract
 (5)
.Occurrence of CRC 
may be dependent on various factors, namely diet, life style and other environmental parameters, including environmental 
and food-borne mutagens 
(6)
. It is estimated that chronic inflammation, likely to be caused by a dysregulated intestinal 
microbiota, contributes to approximately 20% of all CRC cases 
(7, 8)
. 5-Fluorouracil (5-FU) is still a widely used anticancer 
drug. Since 1957, it has played an important role in the treatment of colon cancer and is used for patients with breast and 
other cancers, like those of the head and neck 
(9)
. Due to its structure, 5-FU interferes with nucleoside metabolism and can 
be incorporated into RNA and DNA, leading to cytotoxicity and cell death 
(10, 11)
. .It  is administered  parenterally  because  
it  shows  highly variable oral bioavailability due to the unpredictable and incomplete absorption after  ingestion of  the 
drug  and a marked  bioinactivation  by   dihydropyrimidine dehydrogenase inthe liver and  the mucosal membraneof 
thegastrointestinal  tract
(12, 13)
. Once administrated to a patient, 5-FU tends to distribute randomly through the body with 
low selectively and concentration in the Lumina of the colorectal tissue, resulted in significant toxicities. If an appropriate 
large molecular carrier is chemically linked to the 5-FU [1] with specificity for colorectal cancer cells, this will enhance the 
therapeutic index as well as allow the dosage of the drug to be reduced (if so desired) to minimize toxicities. In addition, 
with the higher specificity and lower toxicity of such prodrug, the oncologist could also titrate the dosage to the level that a 
patient could maximally tolerate, thus maximizing the efficacy and the likelihood appositive outcome for the patient. Large 
molecule carriers include ethylene or acrylic acid polymers, polysaccharides, hydroxyl acid polymers, and amino acid 
polymers, etc
. (14)
. 
 
[1] 
    Because of this specific linkage, the 5-FU prodrug cannot be digested or hydrolyzed in the upper gastrointestinal tract 
and therefore is delivered specifically to the colorectal area. Once arriving at the colorectal area, the 5-FU will be released 
by hydrolysis of the prodrug by bacterial enzymes in the lower intestinal tract 
(15)
. An association between inflammation 
and cancer has been suggested for a long time and it is now well-recognized that inflammation is involved in 
carcinogenesis in several tissues 
(16)
. The development of hepatocellular carcinoma (HCC) caused by hepatitis B virus or 
hepatitis C virus (HCV) infection , gastric cancer caused by H. pylori infection , and colitis associated cancer caused by 
ulcerative colitis  are representative examples of inflammation-associated carcinogenesis. Various inflammatory mediators 
are highly expressed in inflammatory tissues, and inflammation-triggered anti-apoptosis activity and cell growth cause 
cancer development 
(17)
. Inflammatory bowel disease, such as ulcerative colitis and Crohn‟s disease is a longstanding 
inflammatory disease of intestine with increased risk for colorectal cancer (CRC). Several molecular events involved in 
chronic inflammatory process are reported to contribute to multi-step carcinogenesis of CRC in the inflamed colon. They 
include over-production of free radicals, reactive oxygen and nitrogen species, up-regulation of inflammatory enzymes in 
arachidonic acid biosynthesis pathway, up-regulation of certain cytokines, and intestinal immune system dysfunction 
(18)
.Many compounds belonging to diverse chemical classes have been identified as potential chemopreventive agents, 
including vitamins and minerals, naturally occurring phytochemicals, and synthetic compounds. Understanding the 
molecular mechanisms of cancer chemoprevention is not only important for the safe application of these compounds in 
populations of patients at high risk for cancer, but also allows for further development of novel treatment regimens for 
cancer patients 
(19)
. The most frequently used chemopreventive agents in UC patients are 5-aminosalicylic acid (5-ASA) 
compounds (mesalazine and sulfasalazine) as well as ursodeoxycholic acid (UDCA)
 (20)
.Mesalazine or 5-aminosalicylic 
acid (5-ASA) is a drug widely used in IBDs, mainly UC, for the treatment of mild relapses and maintenance of remission. 
Mesalazine is structurally related to NSAIDs, but unlike these compounds, it is safe and free of serious adverse effects. 
Epidemiological observations indicate that mesalazine can be also chemopreventive for IBD-associated CRC 
(21)
. 
Moreover studies conducted in experimental models of carcinogenesis have shown that the drug has many targets in 
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cancer cells and modulates multiple biological pathways that sustain CRC 
(22)
. The colon has recently received great 
attention as a potential site for the delivery of pharmaceutical moieties. Delivery of drugs via the colon offers numerous 
therapeutic advantages. The successful delivery of drugs to the colon via the gastrointestinal (GI) tract requires the 
protection of a drug from being released in the stomach and small intestine. This can be achieved by the use of a special 
drug delivery system that can protect the drug during its transfer to the colon 
(23)
. Prodrug approach is one of the important 
approaches for targeting drugs to colon. Colon- specific drug delivery through colon-specific prodrug, activation may be 
accomplished by the utilization of high activity of certain enzymes at the target site, relative to non-target tissues 
(24)
. In 
view of these observations, three new derivatives of 5-fluorouracil have been designed, synthesized and characterized. 
2. Results and Discussion 
2.1 The chemistry 
The designated compounds were synthesized according to schemes (1 to 3). A series of intermediates were synthesized 
as precursors of the target compounds by several experimental steps. The physical properties of the synthesized 
compound are showed in table 1. The structure of the final compounds and their intermediates were characterized by 
elemental microanalysis (table2) and infrared spectroscopy (table  
 
Scheme 1: The synthesis of compound 1. 
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2: The synthesis of compound 2. 
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Scheme 3: The synthesis of compound 3. 
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Table(1): The physical data of the synthesized compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
*
) Chloroform: methanol (9:1) 
B) Chloroform: ethyl acetate: methanol (2:2:1). 
C) Toluene: ethyl acetate: formic acid (5:4:1). 
 
 
 
 
 
 
 
Compound Physical 
appearance 
%Yield Melting point 
(
o
C) 
Rf value 
A Brown powder 83 146-148 0.37 A
* 
0.22 B 
0.10 C 
1a White powder 28 245-247 0.88 A
* 
0.56 B 
1b Oily 72 _ _ 
 
1 Dark  brown 
powder 
63 270 
decomposed 
0.60 A
* 
0.53 B 
0.357 C 
2a White fluffy 
powder 
73 161-163 0.64 A
* 
0.58 B 
2 Dark red 
Powder 
79 205-207 0.56 A
* 
0.587 B 
0.37 C 
3a Oily 70 _ 
 
_ 
 
3b Off white 
Powder 
46 148-150 0.48 A
* 
0.30 B 
3c Oily 68 _ _ 
 
3d Yellow powder 62 262-265 
 
0.69 A* 
0.55 B 
3e White powder 51 285 
decomposed 
0.58 A
* 
0.63 B 
3 Orange powder 37 178 
decomposed 
0.20 A
* 
0.133 B 
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Table (2): Elemental microanalysis of the final compounds. 
 
Elemental microanalysis % 
 
 
Chemical formula 
 
 
Compounds 
Found Calculated Element Molecular weight 
52.622 51.37 C C22H15FN4O10 
514.37 
 
 
 
1 
3.094 2.94 H 
11.233 10.89 N 
52.115 50.86 C C20H13FN4O9 
472.34 
 
 
 
2 
2.911 2.77 H 
12.163 11.86 N 
52.187 50.96 C C20H14FN5O8 
471.35 
 
 
 
 
3 
3.142 2.99 H 
15.288 14.86 N 
 
Table (3): The characteristic IR bands of synthesized compounds. 
*
(Str. =   stretching vibration,       ar. = aromatic,     assym. = asymmetric, sym.= symmetric  ) 
Cpd. 
No. 
Characteristic I.R. bands (cm
-1
) 
A 
(3404, 3240 OH str.
*
of phenol), (3068 CH ar.
*
str.), (2600-3034 OH str.of COOH), (1710, 1660 C=O str.of COOH) 
,(1587,1512 C=C ar.str.) ,(1483 N=N str.) ,(927,759 CH ar.out of plane). 
1a 
(3140 NH str.of uracil), (2500-3000 OH str. Of COOH), (3070 CH ar. Str.),( 2933&2831  asym.
*
&sym
*
.CH2 str.) 
,(1722 C=C-F str. of uracil) ,(1693 C=O str. of COOH) ,(1660 C=O str. of amide) ,(1504 C=C ar.str.) ,(1429 CH 
bend.of CH2) ,(1178 C-F str.of uracil). 
1 
(3240 OHstr.of phenol) ,(3134 NH str. of uracil) ,(3070 CH of benzene) ,(2600-3000 OH str.of COOH) 
,(2933,2831 assym.&sym.CH str. of CH3&CH2) ,(1772 C=O str. of ester) ,(1720 C=C-F  str.of uracil) ,(1670 ,1662 
C=O str.of amide) ,(1560 NH bend.) ,(1541 ,1508 C=C ar.str.) ,(1448 N=N str.). 
2a 
(3148 NH str. of uracil) ,(3073 CH ar.str.) ,(2938,2827 assym. &sym.CH str. of CH2) ,(1724   C=C-F str. of uracil) 
,(1670,1662 C=O str. of amide) ,(1508,1481 C=C ar. Str. overlapped with NH bend. of amide), (1037 C-Cl str.). 
2 
(3400 OH str. of phenol) ,(3078 NH str. of amide) ,(3051 CH ar. Str.) (2933,2823 assym.&sym.CH str.of CH2) 
,(1714 C=C-F str.of uracil) ,(1683 C=O str.of ester overlapped with C=O str. of COOH) ,(1608 C=O str.of amide) 
,(1591 NH bend. f amide) ,(1512,1485 C=C ar.str.) ,(1460 N=N str.) 
3b 
(3238 NH str. of amide) ,(2500-3000 OH str.of COOH) ,(3061 C=C ar.str.) ,(2918,2862 assym.&sym CH str.of 
CH3&CH2) ,(1747 C=O str. of ester) ,(1658 C=O str. of COOH) ,(1612 C=O str. of amide) ,(1577,1483 C=C ar. str. 
overlapped with NH bend. Of amide). 
3d 
(3138 NH str. of amide) ,(3070 CH ar. str.) ,(2931,2831 assym.&sym.CH str. of CH3&CH2) ,(1724 C=O str. of 
ester overlapped with C=C-F str. of uracil) ,(1656 C=O str. of amide) ,(1502,1448 C=C ar.str.&NH bend.of amide) 
,(1055 C-F str. of uracil). 
3e 
(3425 OH str.of phenol) ,(3136 NH str. of amide) ,(3070 C=C ar. str.) ,(2933,2831 assym.&sym. CH str. of CH2) 
,(1722 C=C-F str. of uracil) ,(1672,1660 C=O str.of amide) ,(1506 C=C ar. str.) ,(1089 C-F str. of uracil). 
3 
(3398 OH str. of phenol) ,(3111 NH str. of amide) ,(3084 CH ar. str.) ,(3034 OH str. of COOH) ,(2948 ,2855 
assym.&sym. CHstr.of CH2) ,(1710 C=O str. of COOH overlapped with C=C-F str. of uracil) ,(1591 C=O str. of 
amide) ,(1560,1546 C=C ar. str.overlapped with NH bend.of amide) ,(1479 N=N str.) ,(1064 CF str. of uracil). 
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2.2.Preliminary hydrolysis study of compounds 2&3 at pH 1.5, pH7.8. 
The stability of compounds 2&3 was studied in phosphate buffer solution (pH 1.5) and (pH 7.8) incubated at 37C. The 
rate of hydrolysis was followed spectrophotometrically by recording the decreases in the absorbance of compounds 2&3 
accompanying the hydrolysis at their max (305nm).  The solutions were kept in a water bath at 37C and samples (3ml) 
were withdrawn at appropriate time interval (15, 30, 60,120,240 min.) and the absorbances were recorded at the max of 
each compound. The observed pseudo first rate constants were determined from the slopes of the linear plots of log. 
Concentration versus time. The result are showed in tables (4,5,6 and7) and figures (1, 2,3 and4).  
 
Table (4): The degree of hydrolysis of compound 2 in phosphate buffer (pH 1.5) at different time intervals. 
Time 
(Min.) 
Absorbance at  
305 nm 
Concentration 
(μg/ml) 
Log. concentration 
0 0.6062 15.3824 1.1870 
15 0.5864 14.8708 1.1723 
30 0.5614 14.2248 1.1530 
60 0.5275 13.3488 1.1254 
120 0.4795 12.1085 1.0830 
240 0.4277 10.7700 1.0322 
 
 
Figure (1).  Log concentration of compound 2 incubated in phosphate buffer (pH 1.5) vs. time. 
The half-life was calculated using equation (2), which is derived from the pseudo first order kinetic law. 
  
 
     Therefore; t 1/2=7.86 hrs. 
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Table (5): The degree of hydrolysis of compound 2 in phosphatebuffer (pH 7.8) at different time intervals. 
Time 
(Min.) 
Absorbance at 
 305 nm 
Concentration 
(μg/ml) 
Log. Concentration 
0 0.5988 15.1912 1.1815 
15 0.5716 14.4883 1.1610 
30 0.5582 14.1421 1.1505 
60 0.5011 12.6666 1.1026 
120 0.4367 11.0025 1.0415 
240 0.3624 9.0826 0.9582 
 
 
Figure (2): Log concentration of compound 2 incubated in phosphate buffer (pH 7.8) vs. time. 
The half-life was calculated using equation (2), which is derived from the pseudo first order kinetic    law. 
     Therefore; t 1/2=5.35 hrs. 
 
Table (6): The degree of hydrolysis of compound 3 in phosphate buffer (pH 1.5) at different time intervals. 
Time 
(Min.) 
Absorbance at  
   305 nm 
Concentration 
(μg/ml) 
Log. Concentration 
0 0.5220 15.259 1.1835 
15 0.5206 15.218 1.1823 
30 0.5125 14.979 1.1754 
60 0.5008 14.634 1.1653 
120 0.4868 14.221 1.1529 
240 0.4577 13.362 1.1258 
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Figure (3): Log concentration of compound 3 incubated in phosphate buffer 
(pH1.5) vs. time. 
The half-life was calculated using equation (2), which is derived from the pseudo first order kinetic law. 
     Therefore; t 1/2=20.61 hrs. 
Table (7): The degree of hydrolysis of compound 3 in phosphatebuffer (pH 7.8) at different time intervals. 
Time 
(Min.) 
Absorbance at 
 305 nm 
Concentration 
(μg/ml) 
Log. Concentration 
0 0.4491 13.109 1.1176 
15 0.4412 12.876 1.1097 
30 0.4326 12.622 1.1011 
60 0.4287 12.507 1.0971 
120 0.4076 11.884 1.0749 
240 0.3873 11.286 1.0525 
 
 
Figure (4): Log concentration of compound 3 incubated in phosphate buffer (pH 7.8) vs. time. 
The half-life was calculated using equation (2), which is derived from the pseudo first order kinetic law. 
  Therefore; t 1/2=18.97 hrs 
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3. Experimental 
3.1. General 
    Chemicals used in the synthesis were of analytical grade. The melting points of the compounds and their intermediates 
(uncorrected) were determined by capillary tube method on Barnstead Electrothermal (USA) and FT-IR spectra were 
recorded on FT-IR spectrophotometer Shimadzu (Japan) at the college of pharmacy /University of Baghdad. The CHNO 
analysis was carried out using Euro-vector EA3000A(Italy).Ascending thin layer chromatography(TLC)was run on silica gel 
60 F254 pre-coated aluminum sheets, Merck (Germany) to check the purity and the reaction
,
sprogress.The detection of 
derivatives was done using UV254nm lamp and the chromatograms were eluted by three solvent systems: 
A) Chloroform: methanol (9:1) 
(25)
. 
B) Chloroform: ethyl acetate: methanol (2:2:1). 
C) Toluene: ethyl acetate: formic acid (5:4:1). 
 
3.2. Chemical Methods 
3.2.1 Synthesis of 3-carboxy-4-hydroxybenzenediazonium chloride (compound A1) 
(23)
. 
In 500ml conical flask, 5-aminosalicylic acid (3.06g, 20mmol) was dissolved in a mixture of concentrated HCl (20ml), water 
(50ml) the resulting solution was stirred and cooled in an ice bath to 0С°. Then a cold solution of sodium nitrite (6.9g, 
100mmol) in water (15ml) was placed in a dropping funnel and added drop wise into the first solution during 15min.the 
temperature should not be allowed to rise above 10С°.The last quantity of the sodium nitrite solution was added more 
slowly and after stirring for 3-4 minutes, a drop of the solution diluted with 4 drops of water was tested with potassium 
iodide-starch; if no immediate blue color was obtained at point of contact with the paper, a further amount of sodium nitrite 
solution was added. The testing was continued every 5 minutes until an immediate blue color was obtained. The reaction 
mixture was further stirred for 20min. in an ice bath at 0-5С°. The diazonium salt formed was used immediately in the next 
step. 
3.2.2 Synthesis of 5, 5'-(diazene-1, 2-diyl)bis(2-hydroxybenzoic acid) (compound A) (Azo bond formation)
( 23)
. 
Salicylic acid (2.76g, 20mmol) was dissolved in (50ml) of (10%) NaOH solution in a suitable beaker immersed in an ice 
bath. The solution was stirred vigorously and the temperature was kept below 5С°. The cold diazonium salt solution from 
the previous step (compound A1) was placed in a dropping funnel, then it was added drop by drop to the cooled, stirred 
salicylic acid solution, a brown color was developed and a brown crystals soon separated in a good yield, at the end of the 
addition the mixture was stirred in an ice bath for further 1hr. The product was collected by filtration and washed with water 
(3x50ml) and dried under vaccum overnight at room temperature. 
3.2.3 Synthesis of 4-(5-fluoro-2, 4-dioxo-3, 4-dihydropyrimidin-1(2H)-yl)-4-oxobutanoic acid (Compound 1a) 
(26)
. 
To a stirring solution of 5-FU (3.9g, 30mmol) in dry dioxane (50ml), succinic anhydride (3g, 30mmol) was added. The 
mixture was refluxed for 8hours and stirred overnight at room temperature. Solvent was removed; the residue was basified 
with saturated solution of sodium bicarbonate (30ml), stirred for 15min. and filtered. The filtrate was acidified with 
concentrated HCl to PH 2 and cooled; a white precipitate produced which was filtered and washed twice with distilled 
water (50ml). The precipitate was dried to give N-substituted succinamic acid derivative (1a). 
3.2.4 Synthesis of4-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-oxobutanoylchloride. (Compound1b). 
Compound 1a (1.15g, 5mmol) was suspended in dry chloroform (20ml) in around bottom flask, the mixture was stirred in 
an ice bath where the temperature should be below 0С°, then thionyl chloride (0.7ml, 10mmol) was added drop wise over 
a period of 30minutes with continuous stirring. After completing the addition the temperature was allowed to reach room 
temperature and reflux was then started at about 75-80С° for 3hours. The solvent and the excess thionyl chloride were 
evaporated by rotary evaporator followed by re-dissolving in chloroform and re-evaporation several times to ensure getting 
rid of the side products (HCl and SO2 gases), leaving a white oily residue which was used immediately in the next step 
without further purification. 
3.2.5 Synthesis of 5-((3-carboxy-4-((4-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-oxobutanoyl) oxy) 
phenyl) diazenyl)-2-hydroxybenzoicacid. (Compound1)
(27)
. 
Compound 1b (0.9g, 3.62mmol) was dissolved in a mixture (40ml) of dry acetone and THF (2:1) and was added drop wise 
to compound A (1g, 3.31mmol) which was dissolved in dried DMF (30ml) containing TEA (0.35g, 3.31mmol) with 
continuous stirring in an ice bath for 3 hours. Stirring was continued at room temperature for further 20 hours. The organic 
solvents were evaporated under vaccum to give a crude residue which was triturated with acetone several times and then 
recrystallized from water: acetone (1:5) and was dried in an oven at 40С°. 
3.2.6 Synthesis of 1-(2-chloroacetyl)-5-fluoropyrimidine-2, 4(1H, 3H)-dione. (Compound 2a) 
(28, 29)
. 
A mixture of 5-FU (1.3g, 10mmol) and dry TEA (1.01g, 10mmol) in dry dichloromethane (25ml) was cooled in an ice salt 
mixture to -10С°. To this reaction mixture, chloroacetyl chloride (0.8ml, 10mmol) in dry chloroform (25ml) was added drop 
wise through a dropping funnel with constant stirring over a period of 1hour maintaining the temperature constant. The 
reaction mixture was stirred further for 5hrs. The temperature then was allowed to reach room temperature and reflux was 
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started at 80С° for 3hours, Solvents were removed and the residue was washed with sodium bicarbonate solution (5% 
w/v, 30ml) and subsequently with cold water (50ml). The crude product was dried and on recrystallization from ethanol 
afforded white fluffy powder (compound 2a). 
3.2.7 Synthesis of 5-((3-((2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-oxoethoxy)carbonyl)-4-
hydroxyphenyl)diazenyl)-2-hydroxybenzoic acid. (Compound 2)
(29)
. 
A mixture of the chloroacetylchloride derivative (compound 2a) (2.06g, 10mmol), compound A (3.02g, 10mmol) and 
sodium bicarbonate (0.84g, 10mmol) in dry acetone (100ml) was refluxed for 15-20hours. After 16hours, the solvent was 
removed and the residue was triturated with acetone several times then recrystallized from ethanol to give dark red 
powder (compound 2). 
3.2.8 Synthesis of 2-(chlorocabonyl) phenyl acetate. (Compound 3a). 
Acetylsalicylic acid (4.5g, 25mmol) was dissolved in dry chloroform (30ml) in around bottom flask; the mixture was stirred 
in an ice bath where the temperature should be below 0С°. Then thionyl chloride (3.5ml, 50mmol) was added drop wise 
over a period of 30min. with continuous stirring. After completing the addition the temperature was allowed to reach room 
temperature and reflux was then started at about 75-80С° for 4hrs. the solvent and the excess thionyl chloride were 
evaporated with rotary evaporator followed by re-dissolving in chloroform and re-evaporation several times to ensure 
getting rid of the side products (HCl and SO2 gases) leaving a colorless oily residue (3.48g) which was used immediately 
in the next step without further purification. 
3.2.9 Synthesis of 2-(2-acetoxybenzamido) acetic acid. (Compound 3b) 
(30)
. 
The whole quantity of compound 3a obtained (3.48g, 17.5mmol) was dissolved in dry chloroform (50ml) and added drop 
wise to a stirred solution of glycine (1.3g, 17.5mmol) in dry pyridine (50ml) with continuous stirring at ice bath. After the 
addition was complete, stirring was continued at room temperature for further 3hours. The reaction mixture was then 
poured into cold water (200ml) followed by addition of few drops of concentrated HCl. The precipitate was collected by 
filtration, washed with D.W (50ml x2) and recrystallized from ethanol. 
3.2.10 Synthesis of 2-((2-chloro-2-oxoethyl) carbamoyl) phenyl acetate.(Compound 3c). 
Compound (3b) (2.37g, 10mmol) was dissolved in dry chloroform (30ml) in around bottom flask; the mixture was stirred in 
an ice bath where the temperature should be below 0С°. Then thionyl chloride (1.4ml, 20mmol) was added drop wise over 
a period of 30min. with continuous stirring. After completing the addition the temperature was allowed to reach room 
temperature and then reflux was started at about 75-80С° for 4hrs. the solvent and the excess thionyl chloride were 
evaporated with rotary evaporator followed by re-dissolving in chloroform and re-evaporation several times to ensure 
getting rid of the side products (HCl and SO2 gases) leaving a yellowish oily residue (1.73g) which was used immediately 
in the next step without further purification. 
3.2.11 Synthesis of 2-((2-(5-fluoro-2,4-dioxo-3,4-dihydrpyrimidin-1(2H)-yl)-2-oxoethyl) carbamoyl) phenyl acetate. 
(Compound 3d). 
The whole quantity of compound (3c) obtained (1.73g, 6.8mmol) was dissolved in dry chloroform (50ml) and added drop 
wise to a stirred solution of 5-FU (0.88g, 6.8mmol) in dry pyridine (50ml) with continuous stirring at ice bath. After the 
addition was complete, stirring was continued at room temperature for further 1hr. and reflux was then started at about 75-
80С° for 3hours, Solvents was evaporated and the obtained residue was triturated with petroleum ether (40-60) several 
times and recrystallized from ethanol and dried to give yellow powder (compound 3d). 
3.2.12 Synthesis of N-(2-(5-fluoro-2, 4-dioxo-3, 4-dihydropyrimidin-1(2H)-yl)-2-oxoethyl)-2hydroxybenzamide. 
(Compound 3e) 
(31)
. 
To a stirring solution of compound (3d) (1.75g, 5mmol) in a mixture of absolute ethanol : DMF (4:1), kept on 18-22С°, an 
aqueous solution of 1N NaOH (12.5ml) was added drop wise over a period of 30min. where the stirred reaction mixture 
was continued for additional 5hrs. then the solvents evaporated, and the residue was dissolved in water and acidified with 
1N HCl to get PH 1. After cooling a white precipitate was appeared which was separated by filtration, washed on the filter 
paper with water and recrystallized from ethanol. 
Synthesis of compound 3. 
This compound was synthesized by following procedures similar to the procedures followed in the synthesis of compound 
A. 
Synthesis of Compound A1 
Compound A1 has been synthesized for preparing compound A and it was prepared again since it was needed in in the 
synthesis of compound 3. 
In 500ml conical flask, 5-ASA (0.77g, 5mmol) was dissolved in a mixture of conc. HCl (5ml) and water (12.5ml). The 
resulting solution was stirred and cooled in an ice bath to 0С°. Then a cold solution of sodium nitrite (1.73g, 25mmol) in 
water (10ml) was placed in a dropping funnel and added drop wise into the first solution during 15min. The last quantity of 
the sodium nitrite solution was added more slowly and after stirring for 3-4 minutes, a drop of the solution diluted with 4 
drops of water was tested with potassium iodide-starch; if no immediate blue color was obtained at point of contact with 
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the paper, a further amount of sodium nitrite solution was added. The testing was continued every 5 minutes until an 
immediate blue color was obtained. After completing the addition of sodium nitrite solution, the reaction mixture was 
further stirred for 20min. in an ice bath at 0-5С°. The diazonium salt formed was used immediately in the next step. 
3.2.13 Synthesis of 5-((3-((2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-oxoethyl)carbamoyl)-4-
hydroxyphenyl)diazenyl)-2-hydroxybenzoic acid. (Compound 3) (Azo bond formation). 
Compound (3e) (1.53g, 5mmol) was dissolved in (12.5ml) of 10% NaOH solution in a suitable beaker immersed in an ice 
bath. The solution was stirred vigorously and the temperature was kept below 5С°. The cold diazonium salt solution from 
the previous step (compound A1) was placed in a dropping funnel, then it was added drop by drop to the cooled, stirred 
solution of compound (3e), an orange color was developed and orange crystals soon separated. At the end of the addition 
the mixture was stirred in an ice bath for further 1 hour. The product was collected by filtration and washed with water 
(3x50ml) and dried at room temperature overnight. 
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